Circulating tumor DNA in Hodgkin lymphoma: biological classification, molecular residual disease, and integration with PET response
4 affiliations
- 12nd Department of Radiology, Medical University of Gdańsk
- 2Central Clinical Laboratory, University Clinical Centre in Gdańsk
- 3Faculty of Health Sciences, Medical University of Gdańsk
- 4Radiology Department, University Clinical Centre in Gdańsk
Abstract
Circulating cell-free DNA (cfDNA) and its tumor-derived fraction, circulating tumor DNA (ctDNA), enable non-invasive tumor genotyping, longitudinal disease monitoring, and molecular residual disease (MRD) assessment. Classical Hodgkin lymphoma (cHL) is particularly suitable for ctDNA-based analysis because malignant Hodgkin and Reed-Sternberg cells usually constitute only a small fraction of the tumor mass, whereas plasma may contain a strong tumor-derived DNA signal. This narrative review summarizes the potential applications of cfDNA-based ctDNA analysis in hematologic malignancies, with a focused emphasis on cHL. We discuss pre-analytical and analytical requirements, including plasma processing, tumor-informed and tumor-naive sequencing, error suppression, droplet digital PCR, and control for clonal hematopoiesis. We then synthesize evidence for ctDNA as a dual-readout biomarker: a baseline tool for non-invasive biological classification and a dynamic measure of molecular response. Published studies identify cHL genomic subtypes, associations with the tumor microenvironment, and prognostic information complementary to PET and conventional risk factors. Age-specific evidence is uneven, and most studies demonstrate analytical feasibility or prognosis rather than benefit from a ctDNA-triggered intervention. ctDNA-MRD should complement FDG-PET/CT; it cannot localize disease or currently replace established staging and response criteria. Routine implementation will require harmonized sample handling, validated assays and reporting thresholds, external quality assessment, and prospective trials demonstrating that ctDNA-guided treatment improves disease control, toxicity, or quality of life.
Related
- Prognostic value of circulating cell-free Epstein-Barr virus DNA CpG methylation in extranodal NK/T cell lymphoma
- Circulating Tumor DNA Testing in Solid Tumors and Lymphoma: ASCO Guideline
- Clonal expansion of CAR-T cells harboring lentivector integration in the PLAAT4 gene following anti-CD19 CAR T-cell therapy in a context of cutaneous T-cell lymphoma
- Exploratory Analysis of Circulating miR‐486‐3p and miR‐21‐5p in Early Detection and Subtype Classification of Luminal A and B Breast Cancer in Peruvian Women
- Serum Free Light Chains in Lymphoma: A Phenotype-First Framework for Biological Interpretation, Analytical Control, and Clinical Use.
BibTeX
@article{bednarek2026circulating,
title = {{Circulating tumor DNA in Hodgkin lymphoma: biological classification, molecular residual disease, and integration with PET response}},
author = {Marta Bednarek and Maria Komossa and Joanna Bidzińska},
journal = {Frontiers in Oncology},
year = {2026},
month = oct,
doi = {10.3389/fonc.2026.1982526},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1982526/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Circulating tumor DNA in Hodgkin lymphoma: biological classification, molecular residual disease, and integration with PET response
AU - Marta Bednarek
AU - Maria Komossa
AU - Joanna Bidzińska
PY - 2026
DA - 2026/10/29
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.1982526
UR - https://www.frontiersin.org/articles/10.3389/fonc.2026.1982526/full
AB - Circulating cell-free DNA (cfDNA) and its tumor-derived fraction, circulating tumor DNA (ctDNA), enable non-invasive tumor genotyping, longitudinal disease monitoring, and molecular residual disease (MRD) assessment. Classical Hodgkin lymphoma (cHL) is particularly suitable for ctDNA-based analysis because malignant Hodgkin and Reed-Sternberg cells usually constitute only a small fraction of the tumor mass, whereas plasma may contain a strong tumor-derived DNA signal. This narrative review summarizes the potential applications of cfDNA-based ctDNA analysis in hematologic malignancies, with a focused emphasis on cHL. We discuss pre-analytical and analytical requirements, including plasma processing, tumor-informed and tumor-naive sequencing, error suppression, droplet digital PCR, and control for clonal hematopoiesis. We then synthesize evidence for ctDNA as a dual-readout biomarker: a baseline tool for non-invasive biological classification and a dynamic measure of molecular response. Published studies identify cHL genomic subtypes, associations with the tumor microenvironment, and prognostic information complementary to PET and conventional risk factors. Age-specific evidence is uneven, and most studies demonstrate analytical feasibility or prognosis rather than benefit from a ctDNA-triggered intervention. ctDNA-MRD should complement FDG-PET/CT; it cannot localize disease or currently replace established staging and response criteria. Routine implementation will require harmonized sample handling, validated assays and reporting thresholds, external quality assessment, and prospective trials demonstrating that ctDNA-guided treatment improves disease control, toxicity, or quality of life.
SN - 2234-943X
ER -